Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
about
Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcomeClinical outcomes of patients with newly diagnosed primary central nervous system lymphoma are comparable on treatment with high-dose methotrexate plus temozolomide and with high-dose methotrexate plus cytarabine: a single-institution experience.Biology and treatment of primary central nervous system lymphoma.Treatment options for central nervous system lymphomas in immunocompetent patients.High-dose chemotherapy with hematopoietic stem cell transplantation for the treatment of primary central nervous system lymphoma.Progress in central nervous system lymphomas.The future of primary intraocular lymphoma (retinal lymphoma).Combined diffusion and perfusion MR imaging as biomarkers of prognosis in immunocompetent patients with primary central nervous system lymphoma.Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma.Pharmacotherapy for primary CNS lymphoma: progress beyond methotrexate?Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoLate relapse in primary central nervous system lymphoma: clonal persistenceR-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium.High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphomaIntensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases.Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma.Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantationCentral nervous system recurrence of systemic lymphoma in the era of stem cell transplantation--an International Primary Central Nervous System Lymphoma Study Group project.New approaches in primary central nervous system lymphoma.How I treat CNS lymphomas.High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions.Recent advances in treatment of primary central nervous system lymphoma.Methotrexate re-challenge for recurrent primary central nervous system lymphomaClinical review: treatment of vitreoretinal lymphoma.Treatment approaches for primary CNS lymphomas.Chemotherapy in newly diagnosed primary central nervous system lymphoma.Primary central nervous system lymphoma: implication of high-dose chemotherapy followed by auto-SCTPathogenesis and management of primary CNS lymphoma.Primary CNS lymphoma: a clinician's guide.Management of elderly patients with primary central nervous system lymphoma.Diagnosis and treatment of primary CNS lymphoma.Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma.Recurrent or refractory primary central nervous lymphoma: therapeutic considerations.Effectiveness and safety of thiotepa as conditioning treatment prior to stem cell transplant in patients with central nervous system lymphoma.Current status of haematopoietic autologous stem cell transplantation in lymphoid malignancies: a European perspective.Whither whole brain radiotherapy for primary CNS lymphoma?Autologous hematopoietic cell transplantation: an update for clinicians.Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma: single-centre experience and literature review.
P2860
Q30457046-9AEFACC0-C5CF-4B71-8FB3-CF7C6A05C526Q33413754-C665C7DF-6230-4D1C-9A62-D17B5CAEA2E4Q33475480-AD7BC2F3-8C48-4B71-A272-7D2616524406Q33510785-361C46D2-3356-4AB1-9A17-1BEA4D6BB668Q33626490-B5790D9D-630C-4FE5-8AA7-EAC58828DA03Q33934406-97EF3F9F-CB6B-48C7-9F74-1528C16CF97EQ33950795-354A621B-0B94-4C9F-9A18-72A9F96096B6Q34050020-C3840E1A-43E8-4711-8271-4D6EA8919055Q34132992-6ADC6F3C-EAEB-40A5-A0B8-384EE48DEA6EQ34190457-8039DC92-E32D-4BC0-8BE7-58F03080A18AQ34943963-A861ADB4-1E5A-482C-8700-EB75951FE4A9Q34977369-56E6CC7E-CFCE-48B9-93F5-F510E84B1729Q35126247-B387390D-5011-4C4A-B288-6D9FE15B9DA6Q35599811-45BB30CE-AA3A-417E-933F-056F45A26B2AQ35995248-2F34638D-06EE-46DE-9E0C-5506FDBDE30CQ36037594-287DBC26-FC9D-4F59-815A-2C9F54FD34A6Q36366649-EF9A001A-A200-46C3-95DB-2ECC6F266F50Q36712741-0B8AA67A-28A5-4C5A-8CAE-CCB71008AD56Q36805865-1F89C8ED-7545-43D0-AA51-02421694E688Q36805893-C89F1D5A-B3F6-4A5D-BB2B-C0C3D8DC724EQ37088471-B885E988-0B67-4607-B04F-5D6C25FD07F0Q37215118-4EBB09BB-C671-4EE1-9996-E1BD6DDDE959Q37330176-335CFDE8-6677-449B-A7BD-19056D05D412Q37345440-C685A049-AF42-4C21-A1DD-B85F3482B7B8Q37600487-610AB433-FBB3-4FAC-BA5A-BDA178F2CF62Q37615331-C1570BA6-4A41-4937-8F37-C5FF9FE5F6F7Q37739428-E68C464D-68D4-4901-9CF7-A40F57A6FDECQ37905596-A56A3E4C-1CA4-492A-BBBF-8E5172604CB6Q37946249-B068B3BB-34B9-4F80-BFC0-5895391A3209Q38010799-B344BF35-2B8B-43F6-870B-7D7EE554BF86Q38053442-66D26187-6899-4F6D-B657-247E2B4E2D45Q38096927-FAF22A3D-7F82-41AB-B125-C08B19519D9DQ38106613-CFCEC6BD-F376-40AE-84AF-1B6AE23E2CB4Q38119420-93FDD7F4-AEDB-43E1-8539-52574480340DQ38140000-C401D229-EFFD-449B-AD40-9DABEDEF2045Q38184642-607C6A86-FAC2-4A86-9A61-87A3DCFFA92EQ38209433-53A9BC56-4134-49FE-82DF-8B940AC4A608Q38228499-664E360F-CA65-4F3D-896D-B0F37C606140Q38248359-46892859-B889-4CF6-A71E-5DA0B0205B5AQ38302642-9BF3D8E2-BC83-4E42-B8AA-61FE6C9233CB
P2860
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Intensive chemotherapy followe ...... e Osseuse-Thérapie Cellulaire.
@en
Intensive chemotherapy followe ...... e Osseuse-Thérapie Cellulaire.
@nl
type
label
Intensive chemotherapy followe ...... e Osseuse-Thérapie Cellulaire.
@en
Intensive chemotherapy followe ...... e Osseuse-Thérapie Cellulaire.
@nl
prefLabel
Intensive chemotherapy followe ...... e Osseuse-Thérapie Cellulaire.
@en
Intensive chemotherapy followe ...... e Osseuse-Thérapie Cellulaire.
@nl
P2093
P356
P1476
Intensive chemotherapy followe ...... le Osseuse-Thérapie Cellulaire
@en
P2093
Anne-Laure Taksin
Antonio Omuro
Bertrand Souleau
Brigitte Dupriez
Brigitte Kolb
Carole Soussain
Christian Gisselbrecht
Emmanuelle Fourme
Francis Witz
Jean-Marc Zini
P304
P356
10.1200/JCO.2007.13.5533
P407
P577
2008-04-14T00:00:00Z